Kumamoto, Japan

Kazuyuki Nakashima


Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 90(Granted Patents)


Location History:

  • Kumamoto, JP (1995 - 2000)
  • Kikuchi, JP (2009)

Company Filing History:


Years Active: 1995-2009

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kazuyuki Nakashima: Innovator in Biopharmaceuticals

Introduction

Kazuyuki Nakashima is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of biopharmaceuticals, particularly in the purification and stabilization of therapeutic proteins. With a total of 3 patents to his name, Nakashima's work has the potential to impact medical treatments significantly.

Latest Patents

One of Nakashima's latest patents is a method for preparing human serum albumin through heat-treatment in the presence of divalent cations. This innovative method purifies human serum albumin by selectively allowing impurities to agglutinate, resulting in a highly purified product. Another significant patent is for a tissue plasminogen activator (t-PA) medicinal composition. This invention enhances the solubility and stability of t-PA or modified t-PA by incorporating nicotinamide or its derivatives into the solvent system, potentially improving therapeutic outcomes.

Career Highlights

Throughout his career, Nakashima has worked with esteemed organizations such as the Juridical Foundation the Chemo-Sero-Therapeutic Research Institute and Teijin Limited. His experience in these institutions has allowed him to develop and refine his innovative approaches to biopharmaceuticals.

Collaborations

Some of Nakashima's notable coworkers include Hiroshi Mizokami and Izumi Mimaki. Their collaborative efforts have contributed to the advancement of research in the field.

Conclusion

Kazuyuki Nakashima's contributions to biopharmaceuticals through his innovative patents demonstrate his commitment to improving medical treatments. His work continues to pave the way for advancements in the purification and stabilization of therapeutic proteins.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…